- Home
- KZR vs CRVO Comparison
KZR vs CRVO Comparison
Compare KZR & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZR | CRVO |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.1M | 47.7M |
| IPO Year | 2018 | 2011 |
Fundamental Metrics
Financial Performance| Metric | KZR | CRVO |
|---|---|---|
| Price | $6.47 | $4.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $6.00 | ★ $23.00 |
| AVG Volume (30 Days) | 25.2K | ★ 105.8K |
| Earning Date | 05-12-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,006,510.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.53 | $3.58 |
| 52 Week High | $7.45 | $14.00 |
Technical Indicators
Market Signals| Indicator | KZR | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 39.95 |
| Support Level | $6.06 | $3.58 |
| Resistance Level | $7.35 | $5.38 |
| Average True Range (ATR) | 0.26 | 0.46 |
| MACD | -0.08 | 0.04 |
| Stochastic Oscillator | 13.64 | 19.46 |
Price Performance
Historical ComparisonAbout KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.